ArticleSurgical neurology international2026
Primary diffuse leptomeningeal glioblastoma: Report of two cases.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary leptomeningeal glioblastoma (PLGBM) is rare and not well understood. Case Description: Case 1: A 26-year-old woman with neurofibromatosis type 1 (NF1) sustained a headache. At presentation, the patient had unilateral abducens nerve palsy. Cerebral magnetic resonance imaging (MRI) detected subtle leptomeningeal enhancements along the brainstem and fourth ventricle, lacking an identifiable intraparenchymal mass. However, an MRI performed 2 months later revealed extensive leptomeningeal lesions over the cerebrospinal axes. Biopsy through a T9 hemilaminectomy led to the diagnosis of glioblastoma (GBM). The patient underwent chemoradiation therapy but died of disease progression 2 years after diagnosis. Case 2: A 78-year-old man presented with somnolence. The patient did not exhibit any focal neurological deficits. Cerebral MRI revealed diffuse leptomeningeal enhancement over the cerebrospinal axes. No intraparenchymal tumor was identified. Biopsy through craniotomy diagnosed GBM. Despite the commencement of chemoradiation therapy, the patient died of disease progression 45 days after diagnosis. Conclusion: PLGBM presents a diagnostic challenge for nonspecific clinical findings. For PLGBM patients complicated by NF1, an aggressive treatment strategy may be recommended for longer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.